Glenmede Trust’s Standard BioTools LAB Stock Holding History

Glenmede Trust’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-235	Closed	-$1K	–	2782
2017 Q2	$1K	Hold	235	–	–	﹤0.01%	2591
2017 Q1	$1K	Buy	+235	New	+$1.49K	﹤0.01%	2591

Other funds holding LAB

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Trust's LAB Position: Q3 2017 in Review

Glenmede Trust sold out of Standard BioTools (LAB) in Q3 2017, closing a stake of 235 shares — an estimated $1K sold.

Glenmede Trust first reported a position in LAB in Q1 2017 and held it in 2 quarters. The position peaked at $1K in Q2 2017. 80 funds tracked by Wall St. Rank hold LAB as of Q3 2017.

Glenmede Trust reported no remaining Standard BioTools position as of Q3 2017 after selling out during the quarter.
Glenmede Trust sold 235 Standard BioTools shares in Q3 2017, an estimated $1K.
Glenmede Trust first reported a position in Standard BioTools in Q1 2017 and held it in 2 quarters.
Glenmede Trust's Standard BioTools position peaked at $1K in Q2 2017.
80 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2017.

Based on Glenmede Trust's 13F filing for Q3 2017, filed 14 Nov 2017.